Show Notes
Episode 1: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host authors of two articles published in the Journal of Thoracic Oncology April 2026 issue.
Dr. Timothy F. Burns, Professor of Medicine in the Division of Medical Oncology at the Ohio State University Comprehensive Cancer Center, joins us to discuss their article "Efficacy and Safety of Olomorasib in Combination with Pembrolizumab in Treatment of Patients with KRAS G12C-Mutant Advanced NSCLC"; and Dr. Paaladinesh Thavendiranathan of Division of Cardiology, Peter Munk Cardiac Center at the Toronto General Hospital and the Director of the Ted Rogers Program in Cardiotoxicity Prevention joins to discuss their article, "The risk of cardiovascular adverse outcomes in patients with thymoma or thymic carcinoma receiving cancer therapy".
Key Topics Covered: • KRAS G12C-mutant NSCLC • Thymoma • Cardiovascular adverse outcomes
Recommended Reading: 1. April 2026 JTO Issue: https://www.jto.org/issue/S1556-0864(26)X2002-0 2. "Efficacy and Safety of Olomorasib in Combination with Pembrolizumab in Treatment of Patients with KRAS G12C-Mutant Advanced NSCLC": https://www.jto.org/article/S1556-0864(25)02936-3/fulltext 3. "The risk of cardiovascular adverse outcomes in patients with thymoma or thymic carcinoma receiving cancer therapy": https://www.jto.org/article/S1556-0864(25)02940-5/fulltext
Podcast Hosts: -Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology; Chief, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA -Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
Podcast Guests: -Timothy F. Burns, MD, PhD, Professor of Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, USA -Dinesh Thavendiranathan, MD, SM, FRCPC, Professor of Medicine, Director, Ted Rogers in Cardiotoxicity Prevention, Peter Munk Cardiac Center, Toronto General Hospital, University of Toronto, Canada
More from JTO Insights
Episode 13: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host authors of two articles published in the October issue of the Journal of Thoracic Oncology. Sai Yendamuri, MD, MBA, FACS, Director of the Thoracic Surgery Research Laboratory at Roswell Park Comprehensive Cancer Center in Buffalo, New York discusses their article Obesity Promotes Lung Carcinogenesis Through Airway Immune Dysfunction; and Mitsuhiro Isaka, MD, PhD, Deputy Chair of the Division of Thoracic Surgery at the Shizuoka Cancer Center in Shizuoka, Japan discusses their article Segmentectomy Versus Lobectomy in NSCLC With Pathologically Invasive Features: A Post Hoc Supplementary Analysis of Multicenter, Phase 3 Trial JCOG0802/WJOG4607L.
In this episode of JTO Insights, recorded at the 2026 World Conference on Lung Cancer, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host the corresponding author of an article published in the JTO 20th Anniversary Series. Dr. Karen Reckamp, Professor of Medicine, Division of Medical Oncology at Cedars Sinai Medical Center, joins us to discuss their article, "The Evolution of Immunotherapy Revolution in Lung Cancer: a 20 Year Perspective."
Episode 11: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host authors of two articles published in the September issue of the Journal of Thoracic Oncology. Shun Lu, MD, PhD, Associate editor for the Journal of Thoracic Oncology; Director of Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine discusses their article SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in China; and Hidetoshi Hayashi, MD, PhD, Department of Medical Oncology, Kindai University Faculty of Medicine discusses their article Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.
Episode Summary Episode 10: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host the corresponding author of an article published in the JTO 20th Anniversary Series. Dr. Jean-Louis Pujol, Professor at Montpellier School of Medicine of Montpellier University in France, joins us to discuss their article, "Lung cancer patient advocacy progress and new challenges since 2006".
Episode 9: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John speak with authors of two articles published in the August issue of the Journal of Thoracic Oncology. Michael J. Grant, MD, Assistant Professor of Medicine in the Section of Medical Oncology at Yale School of Medicine in New Haven, Connecticut, discusses “ERBB2-Activating Mutations and Co-Occurring Genomic Alterations Contribute to Disease Heterogeneity in Patients With ERBB2-Mutant Lung Cancer.” Christian Rolfo, MD, PhD, Division Director of Medical Oncology and Associate Director for Early Phase Clinical Trials at The James Comprehensive Cancer Center, The Ohio State University, discusses “Molecular Profiling Across 80,000 Patients With Lung Cancer.”